William Blair Brokers Increase Earnings Estimates for Biogen

Biogen Inc. (NASDAQ:BIIB - Free Report) - Equities researchers at William Blair lifted their Q2 2025 earnings per share estimates for shares of Biogen in a research report issued on Monday, July 14th. William Blair analyst M. Minter now expects that the biotechnology company will post earnings per share of $4.11 for the quarter, up from their previous estimate of $4.09. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. William Blair also issued estimates for Biogen's FY2025 earnings at $14.74 EPS, FY2026 earnings at $15.94 EPS, Q1 2027 earnings at $4.37 EPS and Q2 2027 earnings at $4.95 EPS.

Biogen (NASDAQ:BIIB - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biotechnology company reported $3.02 EPS for the quarter, missing analysts' consensus estimates of $3.26 by ($0.24). Biogen had a return on equity of 14.03% and a net margin of 15.07%. The business had revenue of $2.43 billion during the quarter, compared to analyst estimates of $2.25 billion. During the same period in the prior year, the firm earned $3.67 EPS. The business's revenue for the quarter was up 6.2% compared to the same quarter last year.

Other analysts also recently issued research reports about the company. HSBC downgraded Biogen from a "buy" rating to a "hold" rating and set a $118.00 price target on the stock. in a report on Monday, April 28th. Oppenheimer set a $205.00 target price on Biogen in a research report on Friday, May 2nd. Piper Sandler reiterated a "neutral" rating and issued a $115.00 target price on shares of Biogen in a research note on Thursday, June 12th. The Goldman Sachs Group lowered their price target on shares of Biogen from $219.00 to $197.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. Finally, Hsbc Global Res cut shares of Biogen from a "strong-buy" rating to a "hold" rating in a report on Monday, April 28th. Twenty investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, Biogen presently has a consensus rating of "Hold" and an average target price of $188.48.

Biogen Stock Performance

Shares of BIIB stock opened at $127.50 on Wednesday. The company has a market cap of $18.68 billion, a P/E ratio of 12.59, a PEG ratio of 1.06 and a beta of 0.14. The business has a 50 day moving average of $128.61 and a two-hundred day moving average of $133.68. Biogen has a 52 week low of $110.04 and a 52 week high of $236.48. The company has a quick ratio of 1.01, a current ratio of 1.44 and a debt-to-equity ratio of 0.27.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Missouri Trust & Investment Co lifted its holdings in Biogen by 23.5% in the 2nd quarter. Missouri Trust & Investment Co now owns 7,810 shares of the biotechnology company's stock valued at $981,000 after acquiring an additional 1,485 shares during the last quarter. TD Private Client Wealth LLC raised its holdings in shares of Biogen by 2,716.7% in the 2nd quarter. TD Private Client Wealth LLC now owns 338 shares of the biotechnology company's stock worth $42,000 after purchasing an additional 326 shares in the last quarter. Public Employees Retirement System of Ohio lifted its stake in Biogen by 1.1% during the second quarter. Public Employees Retirement System of Ohio now owns 45,355 shares of the biotechnology company's stock valued at $5,696,000 after purchasing an additional 492 shares during the last quarter. Ballentine Partners LLC boosted its holdings in Biogen by 43.2% during the second quarter. Ballentine Partners LLC now owns 5,475 shares of the biotechnology company's stock worth $688,000 after buying an additional 1,651 shares in the last quarter. Finally, Fifth Third Bancorp boosted its holdings in Biogen by 34.4% during the second quarter. Fifth Third Bancorp now owns 7,377 shares of the biotechnology company's stock worth $926,000 after buying an additional 1,888 shares in the last quarter. Institutional investors own 87.93% of the company's stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.